Table 4.

Choice of the first-line therapy according to the GIMEMA CML WP proposal [38]

	18–40 years	41–65 years	66–80 years	> 80 year
Low ELTS score	2GTKIs	IM –2GTKIs	IM	IM
Int ELTS score	2GTKIs	2GTKIs	IM–2GTKIs	IM
High ELTS score	2GTKIs	2GTKIs	IM–2GTKIs	IM

Bold indicates the grey zone in which therapy choice is more challenging

GIMEMA Gruppo Italiano Malattie EMatologiche dell'Adulto, ELTS European Treatment and Outcome Study for CML (EUTOS) Long-Term Survival, 2GTKIs second-generation tyrosine kinase inhibitors, IM imatinib mesylate